Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03711162 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
A Phase 3 study, sponsored by Lakefront Biotherapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT03711162: Clinical Trial Phase 3 study, sponsored by Lakefront Biotherapeutics.
NCT03711162 is a Phase 3 study that was terminated before completion, run by Lakefront Biotherapeutics. The registered enrollment target is 525 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03711162, a Phase 3 study, was terminated before completion, sponsored by Lakefront Biotherapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Primary Outcome
FVC (in mL) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
Interventions
- DRUG Placebo
- DRUG GLPG1690
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 3 |
Why NCT03711162 stopped before completion
NCT03711162 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03711162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03711162 about?
NCT03711162 is a clinical study titled "A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care". The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
What is the current status of trial NCT03711162?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2018-11-28. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT03711162?
The interventions under investigation include: Placebo (DRUG), GLPG1690 (DRUG).
Who is sponsoring clinical trial NCT03711162?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03711162's enrollment target sits among peer trials
525 715th of 2000 higher than 1,285 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI